A Qualitative Study of Lived Treatment Experiences and Preferences of Long-Term DMT Users with Relapsing–Remitting Multiple Sclerosis Authors: Clair-Antoine Veyrier, Patrick Vermersch, Olivier Casez, Olivier Heinzlef, Marianne Payet, Laura Luciani, Nicolas Collongues, Martin Duracinsky Published: 2026 ABSTRACT IntroductionRelapsing–remitting multiple sclerosis (RRMS) requires prolonged use of disease-modifying therapies (DMTs), often perceived as burdensome. This study explored the lived treatment experiences of long-term DMT users with RRMS.MethodsThis qualitative, non-interventional study used semi-structured interviews with 20 French-speaking adults with RRMS treated with DMTs for ≥ 10 years. Participants were recruited in France via patient associations and neurology clinics. Exclusion criteria included progressive MS or cognitive impairment. Interviews were conducted remotely and transcribed for thematic analysis using NVivo software, guided by a general inductive and grounded theory framework. Data saturation was monitored, and coding was performed by multiple researchers to ensure reliability.ResultsParticipants (mean age 52 years; 60% female; mean disease duration 20 years) reported strong preference for oral or infrequent infusion DMTs due to lower perceived treatment burden. Frequent home injections were linked with anxiety and reduced autonomy. Voluntary treatment pauses were common, motivated by fatigue or social needs, but constrained by the fear of relapse. Treatment experiences influenced identity and required substantial daily organization.ConclusionLong-term patients with RRMS incorporate DMTs into their routines and identities, favoring less frequent, lower-burden regimens. Findings support the need for personalized care strategies that consider treatment fatigue and promote shared decision-making. Key Summary Points Why carry out this study? Relapsing–remitting multiple sclerosis (RRMS) requires prolonged use of disease-modifying therapies (DMTs), often perceived as burdensome. Treatment experience has been explored mainly at early stages of the disease and remains less explored over time.The proposed study addresses MS management from the perspective of patient experiences and long-term adherence to treatments, focusing on patients with over a decade of DMT use. What was learned from the study? Daily disease management requires substantial cognitive and organizational load and previous treatment experience strongly shapes current treatment perception.Patients with MS develop experiential expertise to better manage their disease. Voluntary treatment pauses were used to manage fatigue or social needs. Why carry out this study? Relapsing–remitting multiple sclerosis (RRMS) requires prolonged use of disease-modifying therapies (DMTs), often perceived as burdensome. Treatment experience has been explored mainly at early stages of the disease and remains less explored over time.The proposed study addresses MS management from the perspective of patient experiences and long-term adherence to treatments, focusing on patients with over a decade of DMT use. What was learned from the study? Daily disease management requires substantial cognitive and organizational load and previous treatment experience strongly shapes current treatment perception.Patients with MS develop experiential expertise to better manage their disease. Voluntary treatment pauses were used to manage fatigue or social needs. Introduction In France, where roughly 134,000 people are diagnosed with multiple sclerosis (MS) [1], a significant proportion are adults over 45 who have been on long-term disease-modifying therapies (DMTs) for more than a decade. DMTs are effective at preventing relapse but not completely preventing the accumulation of disabilities over the course of disease progression and aging [2]. In the case of a recent diagnosis, the medical staff play an important role in the choice of treatment [3], which may subsequently evolve. Patients with a shorter time since diagnosis are less involved with their treatment choice [4]. The choice of whether or not to continue disease-modifying treatment is influenced by various factors, such as the effort felt involved in administration, whether treatment has been successful or not, coping strategies, or well-being without DMT [3]. Patients are concerned by the efficacy of treatment, safety, and convenience [5]. Patient preferences are sensitive to the drug’s mode of administration, perceived benefits, and risks of adverse effects. Intolerance and side effects, lack of efficacy, and route and frequency of administration [4] may lead to a change of treatment. Patients prefer oral treatments to injections and lower frequency of administration [6]. Treatment burden could be defined as the workload of healthcare and its impact on patient well-being [7]. Being a patient requires managing visits to different healthcare appointments, changes of lifestyle, self-monitoring, and drug management. Adherence for oral treatment is higher than with injection [8]. With some immunosuppressive drugs, patients are also concerned with infection [9]. The continuation of DMT treatment in older patients is a matter of debate [10–13], but compliance with DMTs increases with age [14]. Some patients continue DMT treatments for relapsing–remitting multiple sclerosis (RRMS) even after recognition of a progressive form [15], because of fear of a lack of treatments [16]. Insights into patients’ decision-making processes, particularly regarding treatment discontinuation or switching, often prioritize clinical outcomes over personal experiences [17]. Studies have until now also focused on injectable therapies and early-stage patients, with oral DMTs and long-term users being underexplored [18–20]. Few investigations use in-depth qualitative techniques to assess coping mechanisms, emotional resilience, or shifting treatment priorities over extended periods of DMT use [3, 21]. To address these gaps, the present study aimed to explore the lived experiences of long-term DMT adherence among French-speaking adults aged 45 and above with RRMS who had been undergoing continuous DMT for at least 10 years. Using a general inductive qualitative design, in-depth semi-structured interviews were conducted to highlight patient-perceived challenges, adaptive strategies, and evolving treatment expectations across their disease trajectory. Integrating preferences and expectations could improve treatment satisfaction, adherence, and long-term persistence. Methods Study Design and Setting This study was designed as a qualitative, non-interventional, single-country investigation, applying a general inductive approach to explore perceptions and experiences of patients with RRMS who are continuing long-term DMT. The study was conducted in France between December 2024 and May 2025. The methodological framework used semi-structured individual interviews informed by thematic analysis and Grounded Theory principles [22]. The COnsolidated criteria for REporting Qualitative research (COREQ) were used for reporting methods and findings [23]. Participants and Recruitment Participants were over 45 years of age and had been receiving disease-modifying therapies (DMTs) for at least 10 years. Individuals were excluded if they had a diagnosis of progressive MS, significant cognitive impairment, no history of DMT use, or concurrent enrollment in any interventional clinical trials. Recruitment was facilitated through printed flyers distributed in neurologist offices and MS patient associations, inviting eligible individuals to contact the research team directly. Using two recruitment strategies enabled a more diverse sample across different regions of France. Diversification of the sample was based on the gender, age, residential zone type, reported Expanded Disability Status Scale (EDSS) score, socioeconomic status, and length of the disease. We included a 41-year-old participant with over 10 years of receiving DMTs for exploratory purposes: they had a similar length of experience with DMTs but their slightly younger age would modify the lived experience. All participants provided oral informed consent. Data saturation was used to determine the end of inclusions [24]. In qualitative health research, approximately 20 interviews are considered sufficient to reach data saturation, that is the point at which no new concept-relevant information is generated from additional data collection [25]. Data Collection Data collection involved a self-reported sociodemographic questionnaire prior to the interview. The interview thematic guide was developed from a targeted literature review and co-constructed by qualitative researchers (a male researcher PhD, qualitative researcher, and a female researcher with prior MS experience and a PhD in sociology), neurology experts, and partners of patients with MS from the scientific committee board. The interview addressed seven topics: the journey into MS and representations of the disease, the place of MS in life today and their relationship to aging, the place of disease and disease management in everyday life and its consequences, the place of DMT treatments in their daily lives and their relationship to treatment. Minor iterative revisions were made during data collection based on interim coding, saturation monitoring, and team debriefs. The semi-structured interviews were conducted by CAV (male PhD, qualitative researcher) by videoconference or by telephone and were audio recorded. Qualitative Data Analysis Interviews were verbally transcribed using Noscribe software [26] and manually reviewed using Elan software [27]. In a general inductive approach [28–30], two researchers thematically coded several interviews with NVivo 1.6.1 software independently in order to produce a thematic analysis, aimed at extracting the themes and categories developed in the discourse, to reproduce the experience and representations of the participants. Coding mainly involves breaking down the discourse into different units of meaning, labeling them with a code and grouping them by familiarity of meaning into subthemes and themes that meet the objectives. The analysis of the data allows the identification of themes describing the different dimensions of patient experiences. The two researchers compared their coding tree to ensure intercoder agreement, through investigator triangulation [31], followed by reconciliation into a consensus coding tree. All subsequent interviews were coded with this new coding tree by a researcher. Ethical Considerations The study was approved on October 29 2024 (CER-2024–268) by Institutional Review Board Comité d’Ethique de la Recherche (CER) Paris Nord (IRB 00006477) of HUPNVS, Paris Cité University, AP-HP. All subjects provided informed consent to participate in the study. Results Characteristics of Participants with MS The sample was diverse and included a majority of women (58%), with an average age of 52 years (range 41–65) and an average time since diagnosis of 20 years (range 11–34) (Table 1). We included a 41-year-old participant for exploratory purposes which represents a small deviation regarding inclusion criteria. All participants had disability status, and 50% were currently employed. Their socio-professional categories were diverse. Treatment histories showed a mean of 2.4 DMTs per participant, with the majority having experienced three or more therapies. Interferons overwhelmingly dominated as the first-line therapy, fingolimod appeared most frequently as the second-line treatment, and ocrelizumab is the most common third-line option. Participants reported diverse EDSS scores. The interviews had an average duration of 68 min (range 45–86 min).Table 1Characteristics of study participantsSexNumberPercentageMale840%Female1260%Average age (years)52Min–max41–65Living situation In pairs1575% Living alone525% No children630% With children1470% Dependent children632%Employment status Has a job1050% Looking for a job420% Unemployed420% Retired210%Occupational category No professional activity630% Employee210% Intermediate profession315% Manager and senior intellectual profession945%Medical status Average time since diagnosis (years)20 Min–max (years)11–34 Recognition of disabled worker (number)20100% Median expanded disability status scale score reported4 (2–7) Average number of DMTs used2.4 1 mode of DMT treatment (per os, sc, iv)420% 2 modes of DMT treatments (per os, sc, iv)525% 3 modes of DMT treatments (per os, sc, iv)1050% 4 modes of DMT treatments (per os, sc, iv)15%DMT disease-modifying therapy, EDSS Expanded Disability Status Scale Table 1Characteristics of study participantsSexNumberPercentageMale840%Female1260%Average age (years)52Min–max41–65Living situation In pairs1575% Living alone525% No children630% With children1470% Dependent children632%Employment status Has a job1050% Looking for a job420% Unemployed420% Retired210%Occupational category No professional activity630% Employee210% Intermediate profession315% Manager and senior intellectual profession945%Medical status Average time since diagnosis (years)20 Min–max (years)11–34 Recognition of disabled worker (number)20100% Median expanded disability status scale score reported4 (2–7) Average number of DMTs used2.4 1 mode of DMT treatment (per os, sc, iv)420% 2 modes of DMT treatments (per os, sc, iv)525% 3 modes of DMT treatments (per os, sc, iv)1050% 4 modes of DMT treatments (per os, sc, iv)15%DMT disease-modifying therapy, EDSS Expanded Disability Status Scale Characteristics of study participants DMT disease-modifying therapy, EDSS Expanded Disability Status Scale Around 477 codes were used in NVivo, organized into three main themes: care pathway, treatment experience and perception, living with MS (Table 2).Table 2Main themes and subthemes extracted from the analysis of patients’ experiencesCare pathwayAcceptance–denial of the diseaseStarting disease-modifying therapy treatmentChanges in treatmentExpectations and fears regarding a new treatmentTreatment discontinuation and suspensionTreatment outlookTreatment experience and perceptionOral treatmentsHome injectable treatmentsHospital infusion treatmentsLiving with MSBalancing between the omnipresence of MS and distancing oneself from itTaking care of oneself between duty and the fight against MSLifestyle changesAnticipated experience of aging and normalization with ageActivities prevented and adaptationsDifficulties and impact on daily lifeMS multiple sclerosis Table 2Main themes and subthemes extracted from the analysis of patients’ experiencesCare pathwayAcceptance–denial of the diseaseStarting disease-modifying therapy treatmentChanges in treatmentExpectations and fears regarding a new treatmentTreatment discontinuation and suspensionTreatment outlookTreatment experience and perceptionOral treatmentsHome injectable treatmentsHospital infusion treatmentsLiving with MSBalancing between the omnipresence of MS and distancing oneself from itTaking care of oneself between duty and the fight against MSLifestyle changesAnticipated experience of aging and normalization with ageActivities prevented and adaptationsDifficulties and impact on daily lifeMS multiple sclerosis Main themes and subthemes extracted from the analysis of patients’ experiences Acceptance–denial of the disease Starting disease-modifying therapy treatment Changes in treatment Expectations and fears regarding a new treatment Treatment discontinuation and suspension Treatment outlook Oral treatments Home injectable treatments Hospital infusion treatments Balancing between the omnipresence of MS and distancing oneself from it Taking care of oneself between duty and the fight against MS Lifestyle changes Anticipated experience of aging and normalization with age Activities prevented and adaptations Difficulties and impact on daily life MS multiple sclerosis MS Management: The Patient’s Work Self-management of MS and its treatment was consistently described as cognitively demanding. Participants reported a sustained organizational burden involving planning, reminders, appointments, and anticipation of treatment effects. While routinization and planning helped reduce the salience of the disease, this ongoing effort remained experienced as burdensome but necessary in daily life. Doses and injections/infusions were scheduled around activities to limit impact:“After that it is again a matter of organizing around the side effects of the treatment, particularly planning activities at the right time” (P09, male, ~50 years). “After that it is again a matter of organizing around the side effects of the treatment, particularly planning activities at the right time” (P09, male, ~50 years). Moreover, vigilance linked to fatigue guided selective daily commitments and occasional dose modulations were reported to preserve spontaneity and a sense of control. Participants described finely tuned organization of personal and professional activities according to expected drug effects, deploying routines to minimize disruption: MS management involves a multitude of actions depending on the patient’s problems. This active approach requires substantial time and effort from patients. The multiplicity of appointments makes it difficult to distance the disease:“Treatments, medical appointments. I feel like I see doctors all the time. So, this is really difficult. It is painful, in fact. Because we can’t forget” (P19, female, ~50 years). “Treatments, medical appointments. I feel like I see doctors all the time. So, this is really difficult. It is painful, in fact. Because we can’t forget” (P19, female, ~50 years). The orchestration work (phone reminders, calendars, preparation) was viewed as necessary care despite the burden it imposed:“Everything I do for myself today is necessary… but it’s burdensome on a daily basis” (P14, female, ~45 years). “Everything I do for myself today is necessary… but it’s burdensome on a daily basis” (P14, female, ~45 years). Modes of Treatment Administration The majority of participants had experience during their disease of injectable treatment at home or in hospital. If this route of administration was indifferent to several participants who tolerated the mode of administration and side effects well, subcutaneous injection treatment was mostly experienced as a difficult period. Home-based injections were described as burdensome (painful, requiring repetitions, and needing cold storage) and provoking anxiety, prompting adjustments around work schedules, weekends, or sporting activities to mitigate adverse effects. Reliance on a caregiver for administration amplified the emotional imprint of treatment and limited spontaneity:“In the end, it was my husband who learned to do them and who did them” (P19, female, ~55 years). “In the end, it was my husband who learned to do them and who did them” (P19, female, ~55 years). In contrast, more spaced-out regimens (monthly or semiannual infusions) and certain oral agents were perceived as notable improvements, reducing the intrusion of therapy into everyday life; therapeutic history strongly modulated these judgments:“I’ve experienced the worst” (P17, female, ~50 years). “I’ve experienced the worst” (P17, female, ~50 years). Patients reported that the complexity, frequency, and adverse effects of DMTs, especially injectable ones, impacted their daily routines, autonomy, and social life; oral administration and less frequent infusions were perceived as more manageable:“It’s really easy, actually. It’s even less burdensome than tablets” (P13, female, ~50 years). “It’s really easy, actually. It’s even less burdensome than tablets” (P13, female, ~50 years). Trajectory of Change: Perceptions of Improvement or Degradation Half of the respondents had three types of DMTs at the time of the interview. Only four had only one treatment. The change of treatment is mainly related to the evolution of the disease: the occurrence of a relapse or new examination findings may prompt consideration of a treatment change. Switching treatment may cause fear on the part of patients who are accustomed to treatment:“So, I was afraid at first, the time to get used to a new treatment, because side effects had been my main concern. So, I was afraid to say, oh there, the time to get used to, to bear, will I manage? Yes, I was a little anxious” (P11, female, ~45 years). “So, I was afraid at first, the time to get used to a new treatment, because side effects had been my main concern. So, I was afraid to say, oh there, the time to get used to, to bear, will I manage? Yes, I was a little anxious” (P11, female, ~45 years). Similarly, the change of treatment is accompanied by a transition period that forces management of side effects:“She told me, yeah, it’s revolutionary because it’s a stamp and it’s more of a sting. So, it’s great, it’s one stamp a day and everything. She sold it well to me. Except there were side effects. It was complicated, what, the implementation. But hey, once I could put up with it, it was fine” (P13, female, ~50 years). “She told me, yeah, it’s revolutionary because it’s a stamp and it’s more of a sting. So, it’s great, it’s one stamp a day and everything. She sold it well to me. Except there were side effects. It was complicated, what, the implementation. But hey, once I could put up with it, it was fine” (P13, female, ~50 years). Treatment changes can be experienced as a release and are impacted by previous experience. Participants consistently described relief when shifting from frequent home injections to oral regimens or infusions spaced monthly to six‑monthly, citing simpler routines, less intrusion, and greater autonomy.“And it was a liberation [...]. So, no, no, no, really, it was an extraordinary change. No more stitches, the little tablet, you can travel, you can do whatever you want, it was easy. Very simple” (P19, female, ~50 years). “And it was a liberation [...]. So, no, no, no, really, it was an extraordinary change. No more stitches, the little tablet, you can travel, you can do whatever you want, it was easy. Very simple” (P19, female, ~50 years). Hospital-based infusions were reported as less burdensome due to their infrequency, sometimes experienced as a break in the week:“But/actually took it as a break in my week, at first I was still on sick leave, but after even at work, for me my day in the hospital... it was almost a vacation” (P07, female, ~45 years). “But/actually took it as a break in my week, at first I was still on sick leave, but after even at work, for me my day in the hospital... it was almost a vacation” (P07, female, ~45 years). Past experiences shaped preferences and adaptations. Thus, the transition from home injectable to hospital care can be experienced positively:“I prefer to do one treatment every six weeks than three bites a week. I’ve known the worst. It was a dream. People, when they told me four weeks, I’m ‘wow.’ Too cool. And now, six weeks” (P17, female, ~50 years). “I prefer to do one treatment every six weeks than three bites a week. I’ve known the worst. It was a dream. People, when they told me four weeks, I’m ‘wow.’ Too cool. And now, six weeks” (P17, female, ~50 years). The same is true when switching, for example, from an injectable treatment to an oral treatment: If switching from home injection to hospital care is seen as an improvement by decreasing the frequency of treatment, switching from oral to hospital injection may be seen as a regression:“I feel like I’ve come back to something else, to have regressed in quotation marks in my own freedom. Because it’s a lot more constraining, even if it’s okay, it’s only one injection every six months. Already, it’s not bad. I should almost be happy, but I can’t be happy because I was super happy with each other. So, obviously, it’s not as good” (P19, female, ~50 years). “I feel like I’ve come back to something else, to have regressed in quotation marks in my own freedom. Because it’s a lot more constraining, even if it’s okay, it’s only one injection every six months. Already, it’s not bad. I should almost be happy, but I can’t be happy because I was super happy with each other. So, obviously, it’s not as good” (P19, female, ~50 years). Thus, the perception of a treatment is dependent on the past experiences of patients who may experience the same treatment as an improvement or regression. Intentional Therapeutic Pauses This subsection was based on 94 NVivo codes dedicated to voluntary dose omissions and planned treatment breaks. Some participants occasionally skipped a dose to preserve a sense of normality or to avoid “feeling ill”:“There are days I don’t want to be sick, you know. There are days I just missed my treatment. I didn’t take it” (P15, female, ~45 years). “There are days I don’t want to be sick, you know. There are days I just missed my treatment. I didn’t take it” (P15, female, ~45 years). Certain pauses served leisure or performance goals:“It was three weeks ago, but it wasn’t really for work, it was for a day of off-piste skiing where I needed to be in shape” (P09, male, ~50 years). “It was three weeks ago, but it wasn’t really for work, it was for a day of off-piste skiing where I needed to be in shape” (P09, male, ~50 years). These interruptions were described as spaces of autonomy, negotiated against the fear of relapse: “Stopping? No, because I’d be too afraid of having another disabling flare-up” (P02, female, ~ 50 years), while relying on medical trust: “I trust the medical team, and if they tell me I need treatment, there’s a reason” (P20, male, ~ 60 years). Occasionally, a prior agreement was in place:“I asked my neurologist beforehand, and he said ‘if you miss a week, it’s not a problem’” (P09, male, ~50 years). “I asked my neurologist beforehand, and he said ‘if you miss a week, it’s not a problem’” (P09, male, ~50 years). Pauses were also motivated by social contexts: “If I see a gathering, I don’t take it” (P04, female, ~ 45 years), scheduled around deadlines: “If I have an important meeting the next day that I can’t move, I postpone the dose” (P09, male, ~ 50 years), and fueled by therapeutic fatigue and a long treatment history: “I’d been on that therapy for ten years; it felt like liberation” (P19, female, ~ 50 years). Few patients stopped treatment for an extended period of time. This is the case of P07 who stopped treatments against the advice of his neurologist and changed the neurologist on this occasion:I was glad to have stopped too because I had been at the end of my desires. And that’s it, even if I did a push again, too bad, it’s okay with me […]. Maybe I was unconscious, but no, it was freedom found again. (P07, female, ~45 years) I was glad to have stopped too because I had been at the end of my desires. And that’s it, even if I did a push again, too bad, it’s okay with me […]. Maybe I was unconscious, but no, it was freedom found again. (P07, female, ~45 years) No participant permanently discontinued treatment. Other discontinuations of treatment were forced for medical reasons or the choice of pregnancy. Discussion This qualitative study highlights how patients with RRMS on long-term DMTs progressively incorporate the illness and its treatment into their identity and daily life. Treatment burden is closely tied to the route and frequency of administration, with oral or infrequent infusions perceived as less constraining. Most participants experienced multiple DMTs, with changes motivated by side effects, loss of efficacy, or life stage. Daily disease management requires considerable personal effort, influencing lifestyle, autonomy, and adaptation strategies, while interactions with healthcare professionals shape treatment continuity and patient empowerment. Rather than isolated behaviors, voluntary treatment pauses and adaptations should be understood as part of a broader self-regulation strategy developed over long treatment trajectories. These findings emphasize patients’ capacity to actively balance disease control with quality-of-life considerations. The study findings are generally consistent with existing knowledge on long-term DMT use in RRMS. Beyond confirming preferences for oral or infrequent regimens [8], this study highlights how past therapeutic experiences shape patients’ evaluations of current treatments. Treatment simplicity was not valued per se, but in relation to previously experienced constraints, reinforcing the role of experiential expertise in long-term decision-making. Our findings are coherent with results of patients in Latin America where patients with injectable drugs experienced more side effects than oral and infusion, and oral drugs were believed easy to use [32]. Injectable treatments were perceived as more difficult. Corallo et al. state that injections require better coping strategies to succeed [33]. This study highlights that the perception of current treatment is highly impacted by previous treatment experience. Patients’ expressed a preference for treatments with fewer side effects, and lower administration frequency also aligns with evidence showing that injection frequency and tolerability influence switching decisions [34]. Additionally, the study confirms known barriers to long-term adherence, such as fatigue, lifestyle disruption, and logistical constraints, aligning with prior evidence showing that fatigue predicts both adherence difficulty and EDSS progression [35, 36]. The perceived benefit of DMTs was found to be a key driver in treatment adherence [37]. Daily disease management requires considerable personal effort [38, 39] such as managing appointments and task prioritization [40, 41]. Our findings support literature indicating that treatment changes are often patient-initiated as a result of perceived inefficacy or side effects, matching reported switch rates of 30–50% over a decade [3]. Older age is associated with higher adherence to treatments [14]. This study adds nuance by showing that ‘treatment fatigue’ may prompt intentional pauses, a phenomenon underreported in prior research, which has primarily focused on clinical rather than experiential dimensions of discontinuation [3]. Thus, while largely concordant, our results emphasize underexplored patient-driven dynamics in long-term DMT adherence [3, 42]. In the USA, financial barriers led to 19% of treatment delays or discontinuation [39], a factor less relevant in the French context. Stopping treatment does not necessarily represent an explicit aspiration for patients; they look for an optimal balance between disease control and quality of life. This coping strategy highlights that patients with MS develop experiential expertise: they have gone through the various phases of the disease, observed its clinical and therapeutic evolution. Importantly, patients express a strong desire to regain control over their treatment trajectory, a process supported by a trusting relationship with the healthcare team. Problem-solving and active coping relate to better quality of life [43]. Transitioning toward less intrusive therapeutic modalities—such as oral formulations or infrequent infusions—may enhance patients’ sense of mastery over the disease and foster greater acceptance of the overall care pathway. Limitations This study’s methodological limitations include a single-country sample of 20 participants, which limits generalizability. Purposive recruitment may introduce a selection bias, potentially favoring individuals more engaged with their care. Using different strategies of recruitment mitigates this bias. Patients away from the system of care were not part of this study as we focused on the long-term experience of DMTs. Self-reported measures, such as EDSS estimates and sociodemographic data, may be subject to recall bias. The cross-sectional design and single wave of data collection preclude capturing treatment perceptions over time. Although purposive sampling ensured inclusion of varied long-term RRMS treatment experiences, the sample comprised only French-speaking participants over 45 years of age in France, potentially limiting transferability to other cultural, or healthcare contexts, where access to the variety of DMTs is different. Nevertheless, the study yields valuable insights into patient perspectives on long-term DMT use and may be applicable to similar clinical populations in settings with comparable healthcare systems and sociocultural frameworks, particularly in exploring patient-centered preferences and treatment burdens. Conclusions The findings underscore the multifaceted nature of long-term treatment adherence in patients with RRMS, highlighting the significant psychological, social, and organizational burden associated with DMTs. Clinically, this emphasizes the need for personalized approaches that account for patients’ lived experiences, treatment fatigue, and desire for autonomy. Acknowledging patient-initiated temporary treatment breaks and preferences such as oral or spaced dosing regimens can support adherence without compromising therapeutic outcomes. Integrating experiential knowledge into shared decision-making and tailoring long-term care strategies could alleviate treatment burden while sustaining trust and engagement between patients and healthcare providers.